Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
John F Seymour, John M Bennett, Alan F List, Ghulam J Mufti, Steven D Gore, Pierre Fenaux, Valeria Santini, Joel Hetzer, Stephen Songer, Barry S Skikne, Charles L Beach
British Journal of Haematology | WILEY | Published : 2014
Awarded by Medical Research Council
The authors would like to thank Sheila Truten, BS, MC2, Wynnewood, PA, for editorial and writing assistance, which was supported by Celgene Corporation. The authors are fully responsible for all content and for editorial decisions made for this paper. Celgene Corporation funded the AZA-001 study.